<p>添加</p>
<p><img src="https://imageproxy.pbkrs.com/https://cdn.rttnews.com/images/v4/RTTNews-Logo-224x61.png?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://cdn.rttnews.com/images/v4/RTTNews-Logo-224x61.png"/></p>
<p>将其添加为您在 Google 上的首选新闻来源</p>
<p><img src="https://imageproxy.pbkrs.com/https://cdn.rttnews.com/images/v4/google.png?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://cdn.rttnews.com/images/v4/google.png"/></p>
<p>立即添加</p>
<p>美国梯瓦制药（Teva Pharmaceuticals），作为梯瓦制药工业有限公司（Teva Pharmaceutical Industries Ltd.，股票代码：TEVA）的美国子公司，周一宣布了来自 IMPACT-TD 登记的最新真实世界数据，显示出在有基础情绪障碍的患者中，迟发性运动障碍的诊断存在显著差距。</p>
<p>数据显示，85% 的 18 至 29 岁有情绪障碍的成年人在患有迟发性运动障碍时经历了中度到严重的影响，而只有 23% 的人获得了正式诊断。</p>
<p>分析还发现，患者在首次识别出不自主运动后，平均等待超过 3.5 年才获得正式诊断。</p>
<p>迟发性运动障碍是一种与某些心理健康治疗相关的慢性运动障碍，其特征是无法控制和重复的身体运动。</p>
<p>这些发现已在 5 月 16 日至 20 日在旧金山举行的美国精神病学协会年会上发布。</p>
<p>如有意见和反馈，请联系：editorial@rttnews.com</p>
<p>商业新闻</p>

梯瓦制药

美国制药 ETF - iShares

标普全球医疗股指数 ETF - iShares

纳斯达克生物科技指数 ETF - iShares Nasdaq

基因改革 ETF - ARK

医疗业 ETF - Vanguard

医疗业 ETF - SPDR

IBBQ

<p>梯瓦制药报告显示，在情绪障碍患者中，迟发性运动障碍的诊断存在显著差距，85% 的受影响成年人（年龄在 18-29 岁之间）经历了严重影响，但仅有 23% 获得了正式诊断。患者在症状出现后平均等待超过 3.5 年才得到诊断。这些发现是在美国精神病学会年会上分享的</p>

<p>Add</p>
<div class="lb-trans"><p>添加</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://cdn.rttnews.com/images/v4/RTTNews-Logo-224x61.png" alt="" original-src="https://cdn.rttnews.com/images/v4/RTTNews-Logo-224x61.png"/></p>
<p>as your preferred news source on Google</p>
<div class="lb-trans"><p>将其添加为您在 Google 上的首选新闻来源</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://cdn.rttnews.com/images/v4/google.png" alt="" original-src="https://cdn.rttnews.com/images/v4/google.png"/></p>
<p>Add Now</p>
<div class="lb-trans"><p>立即添加</p>
</div><p>Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (TEVA) on Monday announced new real-world data from the IMPACT-TD Registry showing a significant gap in diagnosing tardive dyskinesia in patients with underlying mood disorders.</p>
<div class="lb-trans"><p>美国梯瓦制药（Teva Pharmaceuticals），作为梯瓦制药工业有限公司（Teva Pharmaceutical Industries Ltd.，股票代码：TEVA）的美国子公司，周一宣布了来自 IMPACT-TD 登记的最新真实世界数据，显示出在有基础情绪障碍的患者中，迟发性运动障碍的诊断存在显著差距。</p>
</div><p>The data showed that 85% of adults aged 18 to 29 with mood disorders living with tardive dyskinesia experienced moderate to severe impact from the condition, while only 23% had received a formal diagnosis.</p>
<div class="lb-trans"><p>数据显示，85% 的 18 至 29 岁有情绪障碍的成年人在患有迟发性运动障碍时经历了中度到严重的影响，而只有 23% 的人获得了正式诊断。</p>
</div><p>The analysis also found that patients waited an average of more than 3.5 years to receive a formal diagnosis after involuntary movements were first recognized.</p>
<div class="lb-trans"><p>分析还发现，患者在首次识别出不自主运动后，平均等待超过 3.5 年才获得正式诊断。</p>
</div><p>Tardive dyskinesia is a chronic movement disorder associated with certain mental health treatments and is characterized by uncontrollable and repetitive body movements.</p>
<div class="lb-trans"><p>迟发性运动障碍是一种与某些心理健康治疗相关的慢性运动障碍，其特征是无法控制和重复的身体运动。</p>
</div><p>The findings were presented at the American Psychiatric Association Annual Meeting being held May 16-20 in San Francisco.</p>
<div class="lb-trans"><p>这些发现已在 5 月 16 日至 20 日在旧金山举行的美国精神病学协会年会上发布。</p>
</div><p>For comments and feedback contact: editorial@rttnews.com</p>
<div class="lb-trans"><p>如有意见和反馈，请联系：editorial@rttnews.com</p>
</div><p>Business News</p>
<div class="lb-trans"><p>商业新闻</p>
</div>

Teva Reports Gap In Tardive Dyskinesia Diagnosis Among Patients With Mood Disorders

rttnews

Invesco Nasdaq Biotechnology ETF

梯瓦制药报告指出，情绪障碍患者在迟发性运动障碍诊断方面存在差距